Amarin Corp Plcuk (AMRN) Change in Inventory (2012 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Change in Inventory of -$19.5 million for Q2 2026, down 221.77% year-over-year from $16.0 million in Q2 2025, and down 58.31% quarter-over-quarter from -$12.3 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Change in Inventory (2012 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Change in Inventory for 15 consecutive years, with -$19.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Inventory fell 221.77% year-over-year to -$19.5 million; the TTM figure through Jun 2026 stood at -$46.8 million (up 53.18% YoY), while the FY2025 annual figure was -$34.9 million, up 66.92% from the prior year.
- Change in Inventory retreated to -$19.5 million in Q2 2026 per AMRN's latest filing, from -$12.3 million in the prior quarter.
- Across five years, Change in Inventory topped out at $52.9 million in Q1 2022 and bottomed at -$67.2 million in Q4 2024.
- Historically, Change in Inventory has averaged -$10.7 million across 5 years, with a median of -$13.3 million in 2024.
- Annual changes were most pronounced in 2024 — Change in Inventory plunged 570.87% — and 2025, when it surged 103.12%.
- Amarin Corp Plc\Uk's Change in Inventory stood at -$23.2 million in 2022, then surged by 56.84% to -$10.0 million in 2023, then slumped by 570.87% to -$67.2 million in 2024, then surged by 103.12% to $2.1 million in 2025, then slumped by 1028.7% to -$19.5 million in 2026.
- Business Quant data shows AMRN's Change in Inventory at -$19.5 million in Q2 2026, -$12.3 million in Q1 2026, and $2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -19.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.51 Mn |
| Jun 30, 2026 | -19.51 Mn |
| Mar 31, 2026 | -12.33 Mn |
| Mar 31, 2026 | -12.33 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | -17.02 Mn |
| Sep 30, 2025 | -17.02 Mn |
| Jun 30, 2025 | -6.06 Mn |
| Jun 30, 2025 | -6.06 Mn |
| Mar 31, 2025 | -13.89 Mn |
| Mar 31, 2025 | -13.89 Mn |
| Dec 31, 2024 | -67.24 Mn |
| Dec 31, 2024 | -67.24 Mn |
| Sep 30, 2024 | -12.68 Mn |
| Sep 30, 2024 | -12.68 Mn |
| Jun 30, 2024 | -18.80 Mn |
| Jun 30, 2024 | -18.80 Mn |
| Mar 31, 2024 | -6.73 Mn |
| Mar 31, 2024 | -6.73 Mn |